Copyright: ©Author(s) 2026.
World J Hepatol. Oct 27, 2026; 18(10): 125505
Published online Oct 27, 2026. doi: 10.4254/wjh.125505
Published online Oct 27, 2026. doi: 10.4254/wjh.125505
Figure 2 Change in liver stiffness in a single patient following 6 months of sodium-glucose cotransporter 2 inhibitor therapy.
A: Baseline liver stiffness corresponding to fibrosis stage F2 (8.31 kPa); B: Liver stiffness after 6 months of sodium-glucose cotransporter 2 inhibitor therapy corresponding to fibrosis stage F0/F1 (6.94 kPa).
- Citation: Khaznadar F, Bojanić K, Khaznadar O, Jurić A, Hefer M, Kralik K, Petrović A, Hrženjak A, Lončar A, Steiner J, Smolić M, Smolić R. Changes in lipid biomarkers, liver stiffness and steatosis following sodium-glucose cotransporter two inhibitor therapy in type two diabetes. World J Hepatol 2026; 18(10): 125505
- URL: https://www.wjgnet.com/1948-5182/full/v18/i10/125505.htm
- DOI: https://dx.doi.org/10.4254/wjh.125505